PRKDC and cancer: Taken together, our data suggested that treatment with CTPI2 enhanced radiosensitivity with inhibitors of EJ-pathways (e.g., PARP or DNA-PKcs), pointing to the metabolic disturbance of HR repair pathway mimicking the HR-ness phenotype in cancer cells.